OSIRIS THERAPEUTICS,INC. (OTCMKTS:OSIR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

OSIRIS THERAPEUTICS,INC. (OTCMKTS:OSIR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Appointment of Independent Director

On May 30, 2017, the Board appointed Mr. David White as an independent director. Mr. White will stand for re-election at the 2017 Annual Meeting of Stockholders. Mr. White has been appointed to serve as a member of the Audit Committee. Mr. White will be entitled to receive the compensation received by Board members under the Company’s standard compensation policy and practices. There is no arrangement or understanding between Mr. White and any other person to which either was selected as a director. Mr. White does not have any direct or indirect material interest in any transaction required to be disclosed to Item 404(a) of Regulation S-K.

A copy of the press release issued by the Company to announce the appointment of Mr. White to the Board is included as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d)  Exhibits

See Exhibit Index attached hereto.


About OSIRIS THERAPEUTICS, INC. (OTCMKTS:OSIR)

Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

OSIRIS THERAPEUTICS, INC. (OTCMKTS:OSIR) Recent Trading Information

OSIRIS THERAPEUTICS, INC. (OTCMKTS:OSIR) closed its last trading session 00.00 at 6.00 with 2,921,453 shares trading hands.